Company intelligence / Profile preview

iQera

Princeton, New Jersey, United Statesiqera.it ↗

Ownership: Private
Employees: ~8
Development stage: Commercial

Overview

iQure Pharma is advancing its lead compound, iQ‑007, a first-in-class EAAT2 Positive Allosteric Modulator for CNS disorders. The company has secured $4M in funding to support a Phase 1 clinical trial targeting epilepsy and other neurodegenerative diseases. Preclinical data suggest potential to address glutamate-mediated neurotoxicity across several indications

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Jagiellonian University laboratory of Prof. Krzysztof Kaminski

Beyond the preview

Go deeper on iQera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iQera.

Explore the full profile